Date | Price Target | Rating | Analyst |
---|---|---|---|
9/6/2024 | $18.00 → $20.00 | Neutral → Underweight | JP Morgan |
11/3/2023 | $33.00 → $16.00 | Buy → Neutral | Goldman |
9/21/2023 | $28.00 | Overweight | Barclays |
3/16/2023 | $33.00 | Outperform | Raymond James |
10/14/2022 | $27.00 → $25.00 | Neutral → Underperform | BofA Securities |
9/6/2022 | $37.00 → $34.00 | Neutral → Overweight | Piper Sandler |
8/5/2022 | $40.00 → $37.00 | Buy → Neutral | BofA Securities |
4/27/2022 | $40.00 | Buy | Goldman |
The agreement builds on Organon's global product portfolio for conditions that impact women disproportionately. Women are three times more likely to experience migraine than men.i Organon (NYSE:OGN), a global healthcare company with a focus on women's health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. This expanded partnership builds on Organon's role as sole distributor and promoter of Emgality in Europe sin
Second quarter 2024 revenue of $1.607 billion, flat year-over-year on an as-reported basis and up 2% at constant currency Second quarter 2024 diluted earnings per share of $0.75 and non-GAAP Adjusted diluted earnings per share of $1.12; both reported and non-GAAP Adjusted diluted earnings per share include $15 million of expense, or $0.05 per share, for acquired in-process research and development (IPR&D) and milestones Second quarter 2024 net income of $195 million and Adjusted EBITDA (non-GAAP) of $513 million Guidance range for full year 2024 revenue narrowed to $6.250 billion to $6.450 billion, mid-point of the range, affirmed; Guidance range for Adjusted EBITDA margin (non-GA
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE:OGN), a global healthcare company with a focus on women's health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $15 million of milestone expense in the second quarter of 2024, representing an impact of approximately $0.05 to both GAAP and non-GAAP earnings per share. These development milestones relate to progress associated with Organon's research collaboration and license agreement with Cirqle Biomedical and its
Second quarter 2024 revenue of $1.607 billion, flat year-over-year on an as-reported basis and up 2% at constant currency Second quarter 2024 diluted earnings per share of $0.75 and non-GAAP Adjusted diluted earnings per share of $1.12; both reported and non-GAAP Adjusted diluted earnings per share include $15 million of expense, or $0.05 per share, for acquired in-process research and development (IPR&D) and milestones Second quarter 2024 net income of $195 million and Adjusted EBITDA (non-GAAP) of $513 million Guidance range for full year 2024 revenue narrowed to $6.250 billion to $6.450 billion, mid-point of the range, affirmed; Guidance range for Adjusted EBITDA margin (non-GA
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE:OGN), a global healthcare company with a focus on women's health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $15 million of milestone expense in the second quarter of 2024, representing an impact of approximately $0.05 to both GAAP and non-GAAP earnings per share. These development milestones relate to progress associated with Organon's research collaboration and license agreement with Cirqle Biomedical and its
First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 million expense, or $(0.05) per share, for acquired in-process research and development (IPR&D) and milestones First quarter 2024 net income of $201 million and Adjusted EBITDA (non-GAAP) of $538 million Full year 2024 financial guidance ranges affirmed Organon (NYSE:OGN) today announced its results for the first quarter ended March 31, 2024. "We entered this year with a clear focus: to d
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously
Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously
Barclays initiated coverage of Organon with a rating of Overweight and set a new price target of $28.00
Company announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia® and Xgeva® (denosumab) biosimilar. Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others. In 2019, it was estimated that 32 million Europeans ages 50 or above had osteoporosis, 25.5 million of which were women
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Pfizer Inc. (NYSE:PFE) Dividend Yield: 5.96% Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and increase
The Companies intend to use the net proceeds from the sale of the Notes to repay a portion of their borrowings under the Credit Facilities' U.S. dollar-denominated "tranche B" term loan and to pay the fees and expenses incurred in connection with the foregoing
4 - Organon & Co. (0001821825) (Issuer)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
10-Q - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
Organon Canada launches 'HER Professional Journey' to support female employees to navigate their career paths, and announces a new commitment to funding menopause-related education KIRKLAND, QC, March 8, 2024 /CNW/ - On International Women's Day, Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, launches HER Professional Journey and is encouraging businesses in Canada to Invest in HER and address the unique health experiences that women face, including in the workplace, so that women can feel supported and empowered at every stage of their career.
NEW YORK, Oct. 13, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the opening of trading on Wednesday, October 18: Lululemon Athletica Inc. (NASD:LULU) will replace Activision Blizzard Inc. (NASD:ATVI) in the S&P 500. S&P 500 and S&P 100 constituent Microsoft Corp. (NASD: MSFT) acquired Activision Blizzard in a transaction completed today, October 13. S&P MidCap 400 constituent Hubbell Inc. (NYSE:HUBB) will replace Organon & Co. (NYSE:OGN) in the S&P 500, S&P SmallCap 600 constituent Onto Innovation Inc. (NYSE:ONTO) will replace Hubbell in the S&P MidCap 400, and Organon & Co will re
Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company's global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs. Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development. Dr. Arjona Ferreira brings over two decades of clinical research and development experience and a strong background in women's health. Most recently, he was CMO